LUGPA Leaders Published in NEJM

LUGPA Past President Neal Shore, MD, and other LUGPA member co-authors had three trials published in the New England Journal of Medicine (NEJM) recently. 

  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
    Neal D. Shore, M.D., Cora N. Sternberg, M.D., and others
    Enzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than placebo plus androgen-deprivation therapy among men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level. The risk of death associated with enzalutamide was 27% lower than with placebo. Adverse events were consistent with the established safety profile of enzalutamide.
  • Olaparib for Metastatic Castration-Resistant Prostate Cancer
    Neal D. Shore, M.D., Johann de Bono, M.B., Ch.B., Ph.D., and others
    In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone.